Moxiva (Moxifloxacin)

Moxifloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This inhibition prevents bacterial DNA from unwinding and re‑joining, leading to bacterial cell death and a bactericidal effect.

The dosage of Moxiva is determined by the prescribing clinician based on the specific infection, patient characteristics, and local guidelines. Patients should follow the prescriber’s instructions and the label directions.

Safety data for moxifloxacin in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Moxiva, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moxiva (moxifloxacin) offers a broader spectrum against both Gram‑positive and Gram‑negative organisms compared with older fluoroquinolones such as ciprofloxacin. It also has enhanced activity against atypical respiratory pathogens, making it a preferred option for certain respiratory infections.

Moxiva should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use after the expiry date.

Moxiva is administered orally, typically as a tablet taken with or without food as directed by the prescriber. The exact administration schedule should follow the healthcare professional’s recommendation.

Serious risks include tendon rupture, especially in patients over 60 or those on corticosteroids; QT interval prolongation leading to cardiac arrhythmias; and severe allergic reactions such as anaphylaxis. Patients should be monitored for these events and advised to seek immediate medical attention if they occur.

Moxiva should be avoided in individuals with a known hypersensitivity to moxifloxacin or other fluoroquinolones, patients with a history of tendon disorders related to fluoroquinolone use, and those taking medications that significantly prolong the QT interval unless benefits outweigh risks.